Journal article

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy

Emily J Lelliott, Carleen Cullinane, Claire A Martin, Rachael Walker, Kelly M Ramsbottom, Fernando Souza-Fonseca-Guimaraes, Shatha Abuhammad, Jessica Michie, Laura Kirby, Richard J Young, Alison Slater, Peter Lau, Katrina Meeth, Jane Oliaro, Nicole Haynes, Grant A McArthur, Karen E Sheppard



Both targeted therapy and immunotherapy have been used successfully to treat melanoma, but the development of resistance and poor response rates to the individual therapies has limited their success. Designing rational combinations of targeted therapy and immunotherapy may overcome these obstacles, but requires assessment in preclinical models with the capacity to respond to both therapeutic classes. Herein, we describe the development and characterization of a novel, immunogenic variant of the BrafV600ECdkn2a-/-Pten-/- YUMM1.1 tumor model that expresses the immunogen, ovalbumin (YOVAL1.1). We demonstrate that, unlike parental tumors, YOVAL1.1 tumors are immunogenic in vivo and can be contro..

View full abstract


Awarded by NHMRC of Australia

Awarded by Melbourne Research Scholarship (University of Melbourne)

Awarded by NHMRC Early Career Fellowship

Awarded by National Breast Cancer Foundation (NBCF) Fellowship

Awarded by NHMRC New Investigator Grant

Awarded by Priority-driven Collaborative Cancer Research Scheme

Funding Acknowledgements

This work was supported by grants from the NHMRC of Australia to GAM, KES, CC & NH (#1100189) and from Pfizer Oncology. EL was supported by a Peter MacCallum Cancer Centre Postgraduate Scholarship, Melbourne Research Scholarship (University of Melbourne; 58616) and a Cancer Therapeutics CRC (CTx) PhD Top Up Scholarship. FSFG was supported by a NHMRC Early Career Fellowship (1088703), a National Breast Cancer Foundation (NBCF) Fellowship (PF-15-008), a NHMRC New Investigator Grant (1140406), and a grant (1120725) awarded through the Priority-driven Collaborative Cancer Research Scheme and funded by Cure Cancer Australia with the assistance of Cancer Australia.